Envafolimab (Synonyms: ASC 22; KN 035) |
| Catalog No.GC66344 |
Envafolimab(ASC 22; KN 035)은 인간화 단일 도메인 항 PD-L1 항체의 재조합 단백질입니다. 821d96072c2d58d8970e76f526b0f6b8Envafolimab은 인간 IgG1 항체의 Fc 단편과 항-PD-L1 도메인의 융합에 의해 생성됩니다. 821d96072c2d58d8970e76f526b0f6b8Envafolimab은 5.25nm의 IC50 값으로 PD-L1과 PD-1 사이의 상호 작용을 차단합니다. 821d96072c2d58d8970e76f526b0f6b8Envafolimab은 항종양 활성을 나타냅니다. 821d96072c2d58d8970e76f526b0f6b8Envafolimab은 고형 종양 연구에 잠재력이 있습니다.821d96072c2d58d8970e76f526b0f6b8
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2102192-68-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nm. Envafolimab shows antitumor activity. Envafolimab has the potential for the research of solid tumors[1][2][3].
Envafolimab (0-2.51 nM) induces T-cell cytokine (IFN-γ) production in a dose- and time-dependent manner[3].
Envafolimab (0.18-0.92 mg/kg; i.p.; four times over 2 weeks) shows antitumor activity with a half-life of ~72 h in NOD-SCID mice (A375 cells)[3].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *